Physician profile
Brian Pachter
NPI 1750571048
$9,469.30
in general payments reported to CMS, 2019-2025
42 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $150 · 2021: $1,406 · 2022: $1,895 · 2023: $1,845 · 2024: $1,794 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,890.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,456.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $937.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $823.26 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $771.08 | 2019-2025 | Eohilia |
| Lilly USA, LLC | $724.04 | 2022-2025 | Mounjaro, Zepbound, Omvoh |
| Abbvie INC. | $620.42 | 2019-2025 | |
| Pfizer INC. | $613.82 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $402.04 | 2021 | |
| Amgen INC. | $382.29 | 2019-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $287.66 | 2022 | |
| Idorsia Pharmaceuticals US INC | $273.42 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $229.77 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $193.37 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Intercept Pharmaceuticals, INC. | $179.50 | 2019-2022 | |
| Medtronic, INC. | $170.64 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Pachter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.